Back pain, sinus trouble and diarrhea: those are the complaints that showed up more often on telmisartan than on placebo in the US hypertension trials. Hair loss is not among them, and the word “alopecia” does not appear in the US Micardis label text or in the UK product information I checked.[1][3]
That leaves telmisartan hair loss to be judged on the story rather than the label: does the timing fit telogen effluvium (TE), is the shedding diffuse, and did anything else happen in the same few months? “Not listed” is not the same as “impossible,” and below is how to work through it with your prescriber.
Medical note: This article is for general education and does not provide personal medical advice. Do not stop or change telmisartan without clinician guidance. If you are not sure whether you are seeing shedding or breakage, start here: Shedding vs Breakage. If the diagnosis is unclear, start here: How Hair Loss Is Diagnosed. If you have scalp pain/burning, pustules/crusting, heavy scale, open sores, facial swelling, or rapid worsening, start here: When to See a Doctor.
Key points
- Alopecia is not listed in the telmisartan labels I read. I found no mention of alopecia or hair loss in the US Micardis label text, the US Micardis HCT page I read, or the UK telmisartan 40 mg SmPC.[1][2][3][4]
- What the US trial data show: events more common than placebo were upper respiratory tract infection (7% vs 6%), back pain (3% vs 1%), sinusitis (3% vs 2%), diarrhea (3% vs 2%) and pharyngitis (1% vs 0%).[1]
- Reported skin reactions are different from hair loss: the post-marketing and UK skin entries are drug eruption, rash, urticaria, erythema and angioedema.[1][3]
- “Not listed” does not mean “impossible.” Any medicine can coincide with shedding, so timing and other triggers still need to be reviewed.
- TE timing is delayed. TE is usually noticed 2 to 4 months after a trigger, and the British Association of Dermatologists (BAD) says around 3 months.[6][7]
- Do not self-stop. If timing fits, the next step is a prescriber-guided review.
- Related on this site: ARB Hair Loss: Risk & Timeline • Losartan Hair Loss: Risk, Timeline & Fixes • Valsartan Hair Loss: Risk, Timeline & Fixes • Olmesartan Hair Loss: Risk, Timeline & Fixes • Irbesartan Hair Loss: Risk, Timeline & Fixes • Medication-Related Shedding • Telogen Effluvium.
Quick navigation
- Key points
- What the product information says (and doesn’t)
- Timeline: onset, shedding phase, recovery
- Pattern clues: TE vs AGA vs AA vs breakage
- When labs matter
- What to do
- When to see a doctor
- FAQ
- References
What the product information says (and doesn’t)
US labeling (Micardis)
- Common trial events: in placebo-controlled hypertension trials (1,455 patients on telmisartan, 380 on placebo), events in at least 1% of patients and more often than placebo were upper respiratory tract infection (7% vs 6%), back pain (3% vs 1%), sinusitis (3% vs 2%), diarrhea (3% vs 2%) and pharyngitis (1% vs 0%).[1]
- Cough: 1.6% with both telmisartan and placebo, so it is not increased.[1]
- Stopping treatment: discontinuation for an adverse event was 2.8% with telmisartan versus 6.1% with placebo.[1]
- Skin entries in the trial section: dermatitis, rash, eczema and pruritus appear among events seen in more than 0.3% of patients, with the label not establishing a causal link to the drug.[2]
- Post-marketing reports: drug eruption (toxic skin eruption, mostly reported as toxicoderma, rash and urticaria), urticaria, erythema, increased sweating, and angioedema, including cases with a fatal outcome. Alopecia is not listed.[1][2]
- Combination product: the Micardis HCT label page I read (telmisartan plus hydrochlorothiazide) has no alopecia entry; its skin-related post-marketing entries are angioedema and drug eruption.[4]
UK product information
- The telmisartan 40 mg SmPC (revised August 2026) lists pruritus, increased sweating and rash as “uncommon,” and angioedema, eczema, erythema, urticaria, drug eruption and toxic skin eruption as “rare.” Alopecia and hair loss do not appear.[3]
How it compares with other ARBs
Alopecia is a post-marketing entry in the US valsartan label, which telmisartan’s post-marketing list does not have.[5] See our valsartan page for the details. DermNet’s list of drugs that cause TE names antihypertensives only as “beta-blockers, ACE inhibitors,” and I found no published case reports of telmisartan-related alopecia.[8]
What this means in practice: an absent label entry lowers the likelihood that telmisartan is the culprit, but it cannot rule it out, because rare reactions may never reach a label. The decision should rest on whether the timeline fits TE, whether the pattern is diffuse, and whether there were other triggers in the same window.
Timeline: onset, shedding phase, recovery
- Onset: the key clue is delay. DermNet says hair fall is noticed 2 to 4 months after the trigger; BAD says it can occur around 3 months after.[6][7]
- Shedding phase: BAD gives 3 to 6 months, and calls TE chronic if it lasts more than 6 months.[7]
- Recovery: DermNet says hair fall tapers back to normal over 6 to 9 months in most cases, and BAD says it may take many months for hair to return to normal volume and thickness.[6][7]
- If a drug is the cause and is stopped under medical advice: DermNet says shedding settles within up to 6 months, with regrowth visible within 3 to 6 months and cosmetic recovery sometimes taking 12 to 18 months.[8]
This delay is why the link is easy to miss: someone starts telmisartan, feels stable for weeks, and only later notices more hair in the shower, on the pillow or on the brush. The same window also fits illness, surgery, weight change or stress.
Pattern clues: TE vs AGA vs AA vs breakage
Most consistent with TE
Medication-linked or trigger-linked TE usually looks like diffuse shedding with a generally normal-looking scalp: more hair fall all over, not one sharply defined bald patch.
TE + androgenetic alopecia overlap
If shedding improves but the part line keeps widening or the crown continues to thin, think about overlap with telogen effluvium vs androgenetic alopecia.
Alopecia areata is a different pattern
If you have patchy, smooth, well-defined bald areas, that is less typical for medication-triggered TE and should raise the question of alopecia areata.
Breakage is not the same as shedding
If you mostly see short snapped hairs, rough texture or frayed ends, that points more toward hair breakage than true root-level shedding.
If the scalp is inflamed, think broader than TE
TE is typically non-scarring and without obvious inflammation. If the scalp is very itchy, red, painful or crusted, a simple TE explanation is incomplete; see Itchy Scalp and Hair Loss.
When labs matter
Not everyone with a plausible timeline needs a broad lab panel. DermNet lists at least a blood count, iron studies and thyroid function tests when the cause is unclear, and BAD mentions blood tests to exclude conditions such as thyroid problems and iron deficiency.[8][7] They matter most when shedding is heavy, persistent or recurrent, or the history suggests iron deficiency, thyroid disease, major weight change, illness or dietary restriction in the same window.
For the site workup roadmap, use: Blood Tests & Workup. For the most common overlaps, see low ferritin and shedding and thyroid hair loss vs TE.
What to do (practical plan)
- Build the timeline: write down the telmisartan start date, any dose changes, and the month shedding became noticeable.
- Confirm the pattern: diffuse shedding vs breakage vs overlapping pattern hair loss vs patchy loss.
- Review stacked triggers: illness, fever, surgery, postpartum timing, dieting, weight loss, thyroid issues, low iron or major stress. BAD notes that for 1 in 3 people with TE no cause is found, and DermNet suggests looking back over the three months before the hair loss began.[7][8]
- Check the exact formulation: telmisartan alone versus a combination such as telmisartan with hydrochlorothiazide, because each ingredient has its own label. See our hydrochlorothiazide page.
- Talk to the prescriber: if the timing fits, discuss whether to wait and watch or consider an alternative, weighing the cardiovascular benefit. Do not self-stop.
- Avoid supplement roulette: BAD advises supplements only if your diet is restricted, and notes that medication does not speed up TE regrowth.[7]
- Track monthly: photos every 4 weeks in the same lighting and angle, to judge the trend rather than day-to-day anxiety.
Stress is a common co-trigger; see Hair Loss After Stress.
When to see a doctor
- Scalp pain, burning, pustules, open sores, or heavy scale/crusting
- Patchy smooth bald spots rather than diffuse shedding
- Obvious eyebrow or eyelash involvement
- Facial, lip or tongue swelling, or hives: seek urgent care, since angioedema is a reported reaction to telmisartan
- Shedding that persists beyond about 6 months or returns in repeated waves
- Unclear diagnosis or rapid worsening
Start here: When to See a Doctor.
FAQ
Does telmisartan cause hair loss?
The labels I read do not list it, and I found no published case reports, so there is no documented link.[1][3] That does not exclude an individual reaction, so the timeline and other triggers still need to be reviewed.
Does that mean telmisartan cannot be related to my shedding?
No. It means the direct label support is weaker than for medicines that do list alopecia. Whether the drug fits depends on timing, pattern and whether other triggers were present in the same window.
Why does shedding start months later?
Because TE is delayed: the trigger shifts more hairs into the resting phase first, and the increased shedding becomes noticeable once those hairs are pushed out, typically 2 to 4 months later.[6]
Is hair loss on telmisartan permanent?
When the pattern behaves like TE, it is non-scarring and generally reversible once the trigger resolves, but recovery is slow: DermNet describes tapering over 6 to 9 months in most cases.[6]
Should I stop telmisartan if I suspect shedding?
No, not on your own. The UK information states that after abrupt cessation blood pressure returns to pre-treatment values over several days, without evidence of rebound hypertension, which means untreated high blood pressure is the likely outcome of stopping.[3] Review the timeline and treatment context with the prescriber first.
References (trusted sources)
- Medlibrary: Micardis (telmisartan) prescribing information — placebo-controlled trial events, discontinuation and post-marketing list
- DrugCentral: Micardis (telmisartan) full label text (patient information revised July 2020; no alopecia entry)
- UK electronic medicines compendium: Telmisartan 40 mg tablets SmPC (revised August 2026)
- Medlibrary: Micardis HCT (telmisartan/hydrochlorothiazide) prescribing information, post-marketing experience
- Medlibrary: Diovan (valsartan) prescribing information, post-marketing experience
- DermNet NZ: Telogen effluvium (hair fall noticed 2–4 months after trigger)
- British Association of Dermatologists (Skin Health Info): Telogen effluvium (around 3 months after a trigger)
- DermNet NZ: Alopecia from drugs